Human normal immunoglobulin G

Therapeutic indications

Human normal immunoglobulin G is indicated for:

Primary immunodeficiency syndromes with impaired antibody production, secondary immunodeficiencies (SID)

Population group: only minors (0 - 18 years old) , adults (18 - 65 years old)

Replacement therapy in adults, children and adolescents (0-18 years) in:

  • Primary immunodeficiency syndromes with impaired antibody production.
  • Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.

* PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Immunomodulatory therapy in CIDP

Population group: only minors (0 - 18 years old) , adults (18 - 65 years old)

Immunomodulatory therapy in adults, children and adolescents (0-18 years):

  • Indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with IVIg.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Human normal immunoglobulin G is contraindicated in the following cases:

Patients with hyperprolinaemia type I or II

at least one of
Proline dehydrogenase deficiency
Hyperprolinemia type 2

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.